<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04662814</url>
  </required_header>
  <id_info>
    <org_study_id>mtiu</org_study_id>
    <nct_id>NCT04662814</nct_id>
  </id_info>
  <brief_title>Extracorporeal Shock Wave Therapy for Dysmenorrhea</brief_title>
  <official_title>the Efficacy of Extracorporeal Shock Wave Therapy for Primary Dysmenorrhea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MTI University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ghada ebrahim El Refaye -Faculty of Physical Therapy, Cairo University, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sohier Mahmmoud El Koseiry- Faculty of Physical Therapy, Cairo University, Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>MTI University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      purpose of this study to investigate the effect of Extracorporeal shock wave therapy on pain&#xD;
      and prostaglandin level in patient with primary dysmenorrhea&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This randomized controlled trial is to determine the effect of shock wave therapy in the&#xD;
      treatment of primary dysmenorrhea.&#xD;
&#xD;
      females are randomly assigned into 2 groups: group A SWT treatment plus dietary modification&#xD;
      during PD (n=25） GROUP B:dietary modification only (n=25）;&#xD;
&#xD;
      Participants in group B will receive dietary modification for three successive months&#xD;
&#xD;
      The numerical rating scale (NRS) and prostaglandin blood level will be recorded and evaluated&#xD;
      before and after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 12, 2020</start_date>
  <completion_date type="Actual">January 27, 2021</completion_date>
  <primary_completion_date type="Actual">December 24, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>group A: shockwave therapy and dietary modification group B: dietary modification</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>numerical rating scale</measure>
    <time_frame>3 months</time_frame>
    <description>Numeric rating scale will be 10 cm digital line with 0 (zero) representing feeling no pain and 10 representing feeling the worst pain, was used to assess the severity of the pain before and after treatment for all females in both groups (A&amp;B).&#xD;
measurement will done twice first one at baseline(will be considered as pre treatment measure) and 2nd on e at 3rd menstrual cycle ( will be considered as post treatment measure)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>prostaglandin</measure>
    <time_frame>3months</time_frame>
    <description>5cm plasma concentrations of prostaglandin F2α was taken from all females and was analyzed in the Laboratory index to determine the prostaglandin plasma level&#xD;
measurement will done twice before after the treatment program.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Primary Dysmenorrhea</condition>
  <arm_group>
    <arm_group_label>shock wave</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>shock wave for primary dysmenorrhea for study group along side to dietary modification</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dietary modification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>dietary modification for primary dysmenorrhea for control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>shock wave therapy</intervention_name>
    <description>Intervention group is by shock wave therapy. A radial shock wave device (EME, ITALY) was used. for 4 sessions (one session before the expected day of period and session per day for day1 , day 2 and day 3 of each menstrual cycle) for three successive periods.</description>
    <arm_group_label>shock wave</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>dietary modification</intervention_name>
    <description>Participants will receive dietary modification for three consecutive months dietary modification will be low caffeine and high water and liquids intake and reduce the uptake of fast food, should be followed for 3 months</description>
    <arm_group_label>dietary modification</arm_group_label>
    <arm_group_label>shock wave</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ages ranged between18 - 25 years old.&#xD;
&#xD;
          2. body mass index (BMI) will not exceed 30kg/m2.&#xD;
&#xD;
          3. females will be diagnosed by the physician as primary dysmenorrhea.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Secondary dysmenorrhea .&#xD;
&#xD;
          2. Mental health problem such as depression and anxiety.&#xD;
&#xD;
          3. Irregular periods&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>MTI</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 22, 2020</study_first_submitted>
  <study_first_submitted_qc>December 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2020</study_first_posted>
  <last_update_submitted>March 20, 2021</last_update_submitted>
  <last_update_submitted_qc>March 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>MTI University</investigator_affiliation>
    <investigator_full_name>shaimaa Mohamed hamed</investigator_full_name>
    <investigator_title>principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dysmenorrhea</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/14/NCT04662814/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

